Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
Key Highlights
- ➤Kymera (KYMR) will report KT-579 Phase 1 healthy-volunteer trial results October 29, 2026
- ➤KT-579 is an investigational first-in-class oral degrader of IRF5
- ➤Results cover single- and multiple-ascending doses in healthy volunteers
- ➤Kymera will host an 8:30 a.m. ET video conference and webcast
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event.
Get started
Create a free account to read the full story.